Key Takeaways
- Solid quarter, pricing still a drag: Consolidated revenue grew 18% YoY to ₹2,197 crores, but pricing pressure on large-volume generics persists and the company can only hope for stabilization in the coming quarters.
- Custom synthesis is the growth engine: The CS segment grew over 40% YoY, fueled by a rich pipeline of Phase-II/III molecules and Biosecure Act opportunities, and the company is investing ₹700 crores in new CS capacity.
- Peptide bets are scaling up: Divi's is moving beyond building blocks into GLP-1 fragments (Tetramer, Decamer), with a pilot plant nearly ready and commercial-scale reactors on order, positioning for the next wave of innovator demand.
- Margins face a long climb back: Management calls a return to historic 35%+ margins "wishful thinking" and is working toward it, but the product mix has shifted and every product can't deliver those levels.
- What to watch next quarter: Any sign of pricing stabilization in generics, new CAPEX guidance, and progress on Kakinada commercialization as Phase-I production begins to ramp.
Generic API: Volume Up, Value Flat
- Volume-value disconnect: Volume growth was double-digit for the API business, but constant-currency value growth was flat, showing the severity of the pricing headwind.
- Where the pressure is: Large-volume products like Naproxen, Gabapentin, and Dextromethorphan face ongoing pricing pressure, but long-term contracts and Divi's scale as one of the largest producers allow it to maintain and even grow market share.
- The stabilization bet: Management has no control over the timing and can only hope pricing stabilizes "in the coming few quarters," a refrain that has now persisted for two years.
- Backward integration as a moat: For every generic molecule it enters, Divi's manufactures from basic raw materials to finished API to control the impurity profile and avoid future regulatory issues.
Dr. Kiran S. Divi: "I wish to stabilize this today, but I don't have control on that. It should happen soon, we are hoping in the coming few quarters things should slowly stabilize."
Custom Synthesis & the Biosecure Act Opportunity
- CS momentum is broad-based: The segment is growing over 40% YoY with several molecules in Phase-II and Phase-III, plus large-volume production for brand companies, and the company is investing ₹700 crores in a dedicated CS capacity expansion.
- Biosecure Act is a real tailwind: Divi's is seeing more Phase-II and Phase-III molecules than before, some already-commercialized CS projects wanting Divi's as a second source, and even interest on the generic side, though that is a longer haul.
- Contrast media is a two-track story: Iodine-based compounds are shipping commercial quantities to brand companies in regulated markets with considerable growth, while gadolinium compounds are still in Phase-III, waiting on innovator regulatory approvals.
- The 50:50 ambition: Management wants the generic-to-CS revenue mix at 50:50, not heavy on either side, which implies CS will continue to outgrow generics for some time.
Peptides: From Building Blocks to Fragments
- The strategic step-up: Divi's initially manufactured protected amino acids (building blocks) for GLP-1 and GLP-2 customers, but innovators are now asking for fragments, and the company is moving to supply Tetramer and Decamer chains via solid and liquid phase synthesis.
- Infrastructure is falling into place: A pilot plant with 50-litre reactors is set up, R&D has manufactured samples, and commercial-scale 500-litre reactors (2-3 units) have been ordered as skid mount units for Unit-1.
- Customer-driven investment: Management will invest further and take fragments forward only when customers approve and the time is right, keeping the capital commitment gated on demand signals.
Dr. Kiran S. Divi: "The peptide building blocks we are actively supplying to the innovators and to the companies. Now we are taking one step forward and building the fragments. So, from the fragments they combine two or three fragments, and the API comes out."
Kakinada & Capex: Building for the Medium Term
- Phase-I is nearly ready: The greenfield Unit-III at Kakinada is progressing rapidly, with production activity across the 200-acre Phase-I expected to gradually begin during FY24-25, starting with validations and pre-chemistry products.
- Revenue is still two years out: Regulatory approvals and customer filings will take another 1-2 years after commercialization begins, so material revenue contribution is a FY26-27 story.
- Phase-II is gated on utilization: Management will consider Phase-II only when utilization reaches about 90%; current capacity across all three units is sufficient at 80-85% maintenance, though a product spike could trigger an immediate look.
- New CAPEX guidance is pending: The company wants to complete existing projects first and will provide updated guidance next quarter or the quarter after.
- Asset turn trajectory: Currently at 0.6-0.7, expected to reach one-to-one in the next 2-3 years, driven by Kakinada capex and new API products arriving in FY26-27.
Margins & the Long Normalization
- Product mix is the structural drag: Material costs ticked up to 40% of sales (from 39%) due to mix shift, and management is clear that the historic peak margins from one exceptional year are not the baseline to model.
- The margin ambition is tempered: Returning to 35%+ margins is "wishful thinking" that the company is working toward, but every product cannot deliver that level of profitability in the current mix.
- Nutraceuticals needs a longer lens: Revenue was flat YoY at ₹178 crores, but management insists the segment should be viewed annually, not quarterly, and is confident of double-digit growth for the full year.
Nilima Prasad Divi: "But yes, the wishful thinking is that what the historic number we had one particular year back in the day, I wouldn't say it's something that we don't desire, we are working towards it, but every product can't be that."
Supply Chain & Regulatory
- Red Sea disruptions are manageable: Freight hikes, long transit times from rerouting, and vessel cancellations are being mitigated by advancing shipping schedules by 3-4 weeks, maintaining safety stocks, and diversifying the supply base.
- Raw material prices are stable for now: Q1 saw a relatively balanced scenario, but management is monitoring global events that could alter the picture.
- US FDA outcome was clean: A general CGMP inspection at Unit-II was completed successfully with only one procedural observation, keeping the regulatory track record intact.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Double-digit growth | Confident of double-digit growth for both API and nutraceuticals segments, volume-based and price-based | FY25 |
| Kakinada Phase-I production | Production activity to gradually begin with validations and pre-chemistry products | During FY24-25 |
| Kakinada revenue contribution | Regulatory approvals and customer filings required before products reach market | 1-2 years after commercialization (FY26-27) |
| Future generics commercialization | Filings planned for completion in the next few months, commercialization to follow | FY26 |
| New product revenues (e.g., Ticagrelor) | Patents expire from 2026, revenues to start flowing as products come off-patent | From FY26 |
| Asset turnover | Improve from 0.6-0.7 to one-to-one, driven by Kakinada capex and new API products | Next 2-3 years |
| Generic-to-CS revenue mix | Target 50:50 split, not heavy on either side | No date |
| New CAPEX guidance | Will be provided after existing projects are completed | Next quarter or the quarter after |
| Kakinada Phase-II consideration | Triggered when utilization reaches ~90% (currently at 80-85%) | Gated on utilization |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Consolidated revenue | ₹2,197 cr, +18% YoY |
| Constant currency revenue growth | 18% |
| Material consumption | 40% of sales revenue, vs 39% in Q4 FY24 and 39% in Q1 FY24 |
| Profit before tax | ₹604 cr, vs ₹492 cr in Q1 FY24 |
| Profit after tax | ₹430 cr, vs ₹356 cr in Q1 FY24 |
| Exports share | 86% of revenue |
| Exports to US and Europe | 70% of revenue |
| Generics to custom synthesis mix | 51%:49% |
| Forex impact | ₹1 cr loss, vs ₹3 cr gain in Q1 FY24 |
| Nutraceuticals revenue | ₹178 cr, flat YoY |
| Capitalized assets during quarter | ₹60 cr |
| Capital work-in-progress | ₹1,062 cr, of which Kakinada project is ₹837 cr |
| Total spent on Kakinada project (incl. advances) | ₹1,018 cr |
| Cash on books | ₹4,229 cr as of June 30, 2024 |
| Receivables | ₹1,942 cr |
| Maintenance capex guidance | ₹250–300 cr per year |
| Asset turnover | 0.6–0.7x currently, expected to reach 1x in 2–3 years |